Korean J Anat.  2004 Oct;37(5):449-457.

Synthetic Bile Acid Derivative HS-1200-induced Apoptosis of Human Osteosarcoma Cells

Affiliations
  • 1Department of Oral Anatomy, College of Dentistry, Pusan National University, Korea. parkbs@pusan.ac.kr
  • 2Department of Anatomy, College of Medicine, Catholic University of Daegu, Korea.
  • 3Department of Anatomy, College of Medicine, Dong-A University, Korea.
  • 4Department of Oral and Maxillofacial Surgery, College of Dentistry, Pusan National University, Korea.

Abstract

Bile acids and synthetic its derivatives induced apoptosis in various kinds of cancer cells and had anticancer effects. However, it wasn`t discovered those materials have apoptosis induced effects on osteosarcoma cells. The present study was done to examine the synthetic bile acid derivatives induced apoptosis on osteosarcoma cells and such these apoptosis events. The synthetic bile acid derivatives, chenodeoxycholic acid (CDCA) induced the cell death on human osteosarcoma (HOS) cells contrary to ursodeoxycholic acid (UDCA). HS-1200, a synthetic derivative of CDCAs, was chosen to experiment apoptosis events in HOS cells. HOS cells treated with HS-1200 showed nucleus condensation, cytochrom c release, Bax/Bcl-xL alteration, activation of caspase-3 and caspase-activated deoxyribonuclease (CAD), and degradation of poly (ADP-ribose) polymerase (PARP). Though this study needs more investigations, these in vitro data suggest that treatment of the synthetic bile acid derivatives can give medical therapy on HOS cells.

Keyword

Synthetic bile acid; Apoptosis; Anticancer effect; Osteosarcoma cells

MeSH Terms

Apoptosis*
Bile Acids and Salts
Bile*
Caspase 3
Cell Death
Chenodeoxycholic Acid
Humans*
Osteosarcoma*
Ursodeoxycholic Acid
Bile Acids and Salts
Caspase 3
Chenodeoxycholic Acid
Ursodeoxycholic Acid
Full Text Links
  • KJA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr